Meletios Therapeutics aim is to fulfill the urgent and large unmet medical need for antiviral treatments against current and emerging viral infections by developing innovative small molecules and defective viral genomes.
This French biotech company was created in April 2020 by a team of high level scientists and experienced biotech managers.
One of our first drug candidate has confirmed its broad-spectrum potential on in vitro and in vivo models on the coronavirus family and influenza H1N1, by demonstrating a dual antiviral and anti-inflammatory activity. This molecule will now be developed and tested in order to fulfill the regulatory requirements and enter into clinical phase II.
Several drug candidates from Meletios portfolio are currently being tested both in vitro and in vivo and will widen our range of antiviral molecules on different RNA viruses. Some of these molecules have already been tested in clinic for other human pathologies, so they will have the two main advantages: a well-known safety profile and an accelerated development.
Meletios Therapeutics’ goal is to become a world leader in the fight against emerging viral infections by developing innovative broad-spectrum therapeutic solutions.